Clinical Trials
9 trialsNCT00084487 2014-05-23
Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00003737 2013-06-25
Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00005027 2013-04-05
Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00005085 2013-02-11
Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006102 2013-02-05
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005817 2013-02-01
Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006262 2012-06-11
Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer
Northwestern University
Phase 2 Terminated
NCT00005997 2010-06-11
Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT00006017 2010-06-10
Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase 2 Completed